新锐医药(06108) - 2025 - 年度业绩

Financial Assets - The fair value of financial assets measured at fair value through profit or loss includes an investment in New Ray Medicine International Holding Limited, which accounts for approximately 5.9% of the group's audited total assets as of December 31, 2024[3] - The investment in New Ray Medicine International Holding Limited is held through a 39% ownership of ordinary shares, representing 39% of the paid-up capital[3] Investment Information - The company advises to refer to the 2024 annual report for detailed historical investment costs, fair value at year-end, and performance during the year[4]